An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Clinical Trials Related to Non-small Cell Lung Cancer
Related studies linked through entity extraction aliases.
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Status
- RECRUITING
- Phase
- PHASE3
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- NA
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
- Status
- RECRUITING
- Phase
- PHASE2
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC
- Status
- RECRUITING
- Phase
- N/A
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
- Status
- RECRUITING
- Phase
- PHASE2
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
- Status
- RECRUITING
- Phase
- N/A
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Status
- RECRUITING
- Phase
- PHASE3
Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW
- Status
- RECRUITING
- Phase
- PHASE2
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer
- Status
- RECRUITING
- Phase
- N/A